Mutations in cancer cells affecting subunits of the respiratory chain (RC) indicate a central role of oxidative phosphorylation for tumourigenesis. Recent studies have suggested that such mutations of RC complexes impact apoptosis induction. We review here the evidence for this hypothesis, which in particular emerged from work on how complex I and II mediate signals for apoptosis. Both protein aggregates are specifically inhibited for apoptosis induction through different means by exploiting with protease activation and pH change, two widespread but independent features of dying cells. Nevertheless, both converge on forming reactive oxygen species for the demise of the cell. Investigations into these mitochondrial processes will remain a rewarding area for unravelling the causes of tumourigenesis and for discovering interference options.
The mitochondrial respiratory chain (RC) consists, as detailed in Figure 1 , of four membrane-bound, multimeric RC complexes (RCCs) and catalyzes the oxidation of reducing equivalents, mainly nicotinamide adenine dinucleotide (NADH), using the terminal electron acceptor oxygen (O 2 ) in the inner mitochondrial membrane (IMM) (Lenaz and Genova, 2010) . The electron transfer mediated by the RC is connected to the final complex, ATP synthase (complex V), which generates ATP. This coupling between RC and ATP synthesis is called oxidative phosphorylation (OxPhos).
Of note, electron leakage can arise all along the RC and lead to reactive oxygen species (ROS) formation (Figure 1) .
Deficiencies in the RC are frequently found in cancer cells. Among the various causes are numerous mutations in the mitochondrial genome (mtDNA) affecting subunits in RCC I, III and IV (Polyak et al., 1998; Ishikawa et al., 2008) , and in nuclear-coded components of complex II (Baysal et al., 2000; Bayley et al., 2005; Hensen and Bayley, 2011) whose assembly factors are likewise mutated (Ghezzi et al., 2009; Hao et al., 2009) . These alterations lead to specific defects of the respiratory chain, which are described in detail below and depicted in Figure 2 . Equally important for RC inhibition is the global metabolic shift from OxPhos to glycolysis (Gatenby and Gillies, 2004; Pelicano et al., 2006) , notably in hypoxia during the early stages of tumourigenesis (Papandreou et al., 2006; Gogvadze et al., 2010) .
MtDNA mutations in cancer affecting RCC I, III and IV Most RCCs are multimeric enzyme aggregates composed of several mtDNA-and nuclear-encoded proteins ( Figure 1 ). MtDNA-derived subunits of RCC I (7/45 subunits: NADH dehydrogenase subunits ND1 to ND6 and ND4L), III (1/11 subunits: cytochrome b) and IV (3/13 subunits, cytochrome c oxidase subunits COXI to III) have been found altered in various types of cancers (Brandon et al., 2006; Lu et al., 2009 ), although they, like their nuclear-encoded counterparts, can also lead to neurodevelopmental impairment, neurodegenerative diseases or cardiomyopathies when mutated Distelmaier et al., 2009; Diaz, 2010; Schapira, 2010) . Consequently, the actual contribution of these mutations to tumourigenesis is an important question-do these mutations act as a significant cause or do they merely constitute a side effect of tumour development, caused by, for example, the combined effect of the intrinsic oxidative stress in cancer cells (Pelicano et al., 2004; Gogvadze et al., 2010) and the low DNA repair capacity for mtDNA (Penta et al., 2001) ? A confounding factor is the multiplicity of the mtDNA, which is present in these organelles in hundreds of copies. Sequencing of the mtDNA revealed heteroplasmy between normal and cancer cells (He et al., 2010) . Few papers have so far described the precise (Gasparre et al., 2008) , for example, mtDNA mutations in the complex I subunits ND2 and ND4-6 were shown to be associated with complex I deficiency and enhanced proliferation (Gasparre et al., 2008) . By the same token, human cells carrying an overexpressed ND5 mutant were associated with a drop in oxygen consumption, increased ROS production, potentiated glucose dependency and enhanced tumour growth (Park et al., 2009) . MtDNA mutations of the complex III subunit COXI were found in 11 to 12% of all prostate cancer patients screened in one study and associated with a complete loss of the COXI protein in tumoral tissues and an increased tumour growth rate (Petros et al., 2005) . Recognizing the inefficient DNA repair and the heteroplasmy of the mtDNA in the mitochondria and hence the complex interrelation of cause and effect, additional techniques were employed to study the role of mitochondrial changes on carcinogenesis. The involvement of mtDNA mutations in RC dysfunction and tumourigenesis was further confirmed through the method of transmitochondrial cybrids (Ohta, 2006) , in which mitochondria from tumour cells are transferred into normal cells and allow study the mtDNA mutations independently of the tumoral nuclear DNA. Using this technique, it was shown that mutations in mtDNA of complex I (ND1) and III (cytochrome b) led to a considerable decrease of both enzymatic activities and to ROS overproduction in thyroid carcinoma (Bonora et al., 2006) . In accordance, another study established that the ND6 mutation confers a high metastatic potential to its cybrid and was associated with a profound complex I deficiency and an overproduction of ROS (Ishikawa et al., 2008) . Finally, another argument for the relevance of mtDNA mutations in cancer progression is made by a cybrid model with a mutant form of ATP6, the mtDNA-coded subunit of ATP synthase (2/16 mtDNA-coded subunits, ATPase 6 and 8; Figure 1 ). This model showed the positive contribution of the ATP6 mutant to tumour growth in mice through a decreased respiration rate, a higher proliferation in culture and a significant resistance to apoptosis (Shidara et al., 2005) . In conclusion, it appears that a major tumourigenic route links mtDNA mutations to (1) the decrease of one or more RCC activities, (2) an impaired electron flux along the Figure 2 Mutations of the respiratory chain components in cancer. The four complexes of the respiratory chain are schematized and the various mutations found in cancer cells that impact RC complex subunits and assembly factors are highlighted: ND1-6 and ND4L (nicotinamide adenine dinucleotide (NADH) dehydrogenase subunits 1-6 and 4L); SDHA-D (succinate dehydrogenase subunits A-D), SDHAF2 (SDH assembly factor 2); cytochrome b; COXI-III (cytochrome c oxidase subunits I-III).
Respiratory chain complexes and apoptosis A Lemarie and S Grimm RC associated with a reduced oxygen consumption, (3) an increase in the electron leakage outside the affected RC leading to an increase of the basal ROS production and to the subsequent alterations of mtDNA, (4) a global resistance to apoptotic processes (Kwong et al., 2007) and finally to (5) an enhanced proliferation and growth instigating the development of tumour formation (Lu et al., 2009) .
Nuclear DNA mutations in cancer affecting complex II Complex II (succinate dehydrogenase (SDH) or succinate coenzyme Q (CoQ) reductase (SQR)) of the mitochondrial respiratory chain is composed of only four subunits (SDHA, SDHB, SDHC and SDHD) and is the only complex to be fully encoded by nuclear DNA. This heteroligomer, which is also a component of the tricarboxylic acid cycle, contains tumour-suppressor proteins (Baysal et al., 2000; Niemann and Muller, 2000; Astuti et al., 2001) . Indeed, germ-line lossof-function mutations of SDHB, SDHD (cytochrome bS (cybS)) and, more rarely, SDHC (cytochrome bL (cybL)) predispose carriers to head and neck paragangliomas (PGLs), extra-adrenal PGLs and pheochromocytomas (PHs). These SDHB/C/D mutations account for 15% of all hereditary cases (Rutter et al., 2010) and, as they implicate loss of heterozygosity by somatic loss of the normal allele, SDHB/C/D are defined as classical tumour-suppressor genes (Baysal, 2008) . It is noteworthy that mutations of the same subunits have also been found in 11-16% of patients with apparently sporadic PGL (Amar et al., 2005; Burnichon et al., 2009) but appear to be absent in sporadic PH (Waldmann et al., 2009; Feichtinger et al., 2011) . Mutated SDHB in those tumours is regarded as a high-risk factor for malignancy, poor prognosis and metastasis (Amar et al., 2007; Boedeker et al., 2007; Gimenez-Roqueplo et al., 2008) . The neuroendocrine tumours PGL and PH are considered as relatively rare with a yearly incidence of 1 to 2 per 1 000 000, respectively (Baysal, 2008) , but complex II mutations have also been found in other types of cancers. SDHB mutations, for example, have been associated with renal cell carcinomas (Neumann et al., 2004; Ricketts et al., 2008) and neuroblastoma (Schimke et al., 2010) , and SDHB or SDHD mutations with papillary thyroid cancer (Neumann et al., 2004) . Mutations in SDHB, SDHC and SDHD have also been detected in hereditary PGL-associated gastrointestinal stromal tumours (McWhinney et al., 2007) and sporadic gastrointestinal stromal tumours (Janeway et al., 2011) . Surprisingly, although numerous germ-line mutations were found in the iron-sulphur (Fe-S) subunit of complex II (Ip, SDHB) and in its two small membrane-anchoring subunits SDHC and SDHD (Bayley et al., 2005) , initially no mutation in its large flavoprotein catalytic subunit (Fp, SDHA) could be detected in patients. Mutated forms of SDHA were only found in a subset of individuals with Leigh syndrome (LS), a neurodegenerative mitochondrial encephalopathy (Rutter et al., 2010) . Only in 2009, Rutter et al. (2010) identified in PGL a relatively rare mutation of SDHAF2 (SDH5), a SDH assembly factor involved in the addition of the flavin-adenine nucleotide (FAD) prosthetic group of SDHA (Hao et al., 2009; . Finally, in 2010, Gimenez-Roqueplo and colleagues (Burnichon et al., 2010) detected the first mutation in SDHA leading to PGL. Both of these studies highlight that at least in some PGL cases SDHA or SDHArelated genes such as SDHAF2 can act as tumour suppressors. Of note, another complex II assembly factor (SDHAF1) was also recently identified but no involvement in PGL/PH was shown. Rather, SDHAF1 mutations were discovered in two families with infantile leukoencephalopathy (Ghezzi et al., 2009 ).
An important common characteristic of these SDH mutations is their effect on the presence of complex II in the IMM of carrier patients. It appears that mutations in SDHA (Burnichon et al., 2010) , SDHB (GimenezRoqueplo et al., 2003; van Nederveen et al., 2009 ), SDHC (van Nederveen et al., 2009 , SDHD (GimenezRoqueplo et al., 2001; Douwes Dekker et al., 2003; van Nederveen et al., 2009 ) and SDHAF2 (Hao et al., 2009) all lead to the complete absence or at least a dramatic decrease of the intact complex II and its enzymatic activity, both in PGL/PH tumours (van Nederveen et al., 2009) and in gastrointestinal stromal tumours (Janeway et al., 2011) . Interestingly, even in the absence of mutations in the coding sequence of complex II subunits, individual SDH genes can also be markedly downregulated in PGL/PH (Blank et al., 2010; Feichtinger et al., 2011) and in other types of cancers (Habano et al., 2003; Putignani et al., 2008) , suggesting that downregulation of RCC proteins in tumours can have similar effects as mutations in the protein sequence.
Metabolic shift and the general RCC inhibition in cancer Although various RCC subunits are mutated in some cancers, in most tumours types the RCC genes are intact but the whole respiratory chain is nevertheless restrained by the metabolic shift of cancer cells from oxidative phosphorylation to glycolysis, an effect that can still be observed at later stages of the tumour, even when the oxygen supply is restored. This so-called Warburg effect may be an adaptation to the growth conditions during early tumourigenesis (Gatenby and Gillies, 2004) and on a molecular level could be caused by the upregulation of hypoxia-inducible factor-1a (HIF1a) in response to ROS and/or succinate accumulation (reviewed in Gottlieb and Tomlinson, 2005; Bayley and Devilee, 2010) . It was hypothesized by Crabtree that glucose accumulation through the glycolytic shift in tumour cells can further decrease oxidative phosphorylation, thereby setting in motion a self-amplifying process (Wojtczak, 1996; Diaz-Ruiz et al., 2011) . Different mechanisms were evoked, as summarized in Table 1 , notably ROS overproduction during glucose catabolism, altering mitochondrial proteins (Yang et al., 1997) .
Concerning ROS, it is noteworthy that direct alteration of the different RCCs by superoxides, hydrogen peroxides or hydroxyl radicals can be observed in isolated mitochondria (Zhang et al., 1990) or in intact cells , leading to post-translational modifications of each complex, such as lipid peroxidation adducts (4-hydroxynonenal or malondialdehyde), carbonylation or nitration of residues and finally to a significant decrease of their respective activities (Choksi et al., 2007 (Choksi et al., , 2008 . In the case of complex II, for example, it was demonstrated that during ischaemia/reperfusion, superoxides can induce a loss of SDHA glutathionylation favouring its nitration by peroxynitrite on tyrosine residues, leading to an impairment of its activity (Chen et al., 2007b (Chen et al., , 2008 . Finally, besides ROS, pH, calcium, other second messengers frequently misregulated in cancer were shown to control the RC, notably nitric oxide and ceramide, a sphingolipid involved in mitochondrial apoptotic signalling and in the response to anticancer agents (Siskind, 2005; Ryland et al., 2011) (Table 1) .
In line with these mechanisms of RC regulation, different cellular signals are able to induce a glycolytic response in cancer cells and were also found to inhibit the respiratory chain. Among them, the proglycolytic role of the already mentioned HIF1a has been extensively studied (Denko, 2008) , and it is now established that this transcription factor can modulate oxidative respiration (Solaini et al., 2010) , as detailed in Table 2 . Briefly, HIF1a can unbalance the ratio between pyruvate dehydrogenase and lactate dehydrogenase in favour of the latter (Semenza et al., 1996; Kim et al., 2006; Papandreou et al., 2006) . Recently, the HIF1a target BNIP3 (Guo et al., 2001 ) was shown to mediate a similar global RC inhibition (Rikka et al., 2011) . Besides these general RC inhibition mechanisms, it was demonstrated that HIF1a can also reduce RCC IV activity through the induction of microRNA-210 (Chen et al., 2010) . Moreover, in PGL/PH tumours, which exhibit high levels of HIF1a, this transcription factor was shown to exert a negative regulatory loop on complex II through the downregulation of SDHB expression. This then amplified, in a feed-back loop, the effect leading to further pseudo-hypoxia and HIF1a stabilization (Dahia et al., 2005; Cervera et al., 2008) . Moreover, hypoxia was shown to further inhibit complex II activity and generate mitochondrial ROS (Paddenberg et al., 2003; Lluis et al., 2007) . Finally, hypoxia and probably HIF1a also inhibit ATP synthase, thereby contributing to OxPhos reduction (Campanella et al., 2009) . Of note, in addition to HIF1a, p53 is also involved in both glucose metabolism (Yeung et al., 2008) and oxidative phosphorylation (Frezza and Gottlieb, 2009) , and the downregulation of p53 activity, as observed in tumours, likely leads to RCC impairment and sustained glycolysis (Table 2) .
Changes in RCC lead to apoptosis resistance The various RC alterations and mutations found in RC complexes imply that their wild-type forms safeguard cells against malignant transformation and that the observed changes abrogate this function. The inhibition of apoptosis is regarded as one of the hallmarks of cancer cells (Hanahan and Weinberg, 2000) . It allows the malignant cells to continuously grow despite the various adverse conditions they encounter. Conversely, apoptosis induction is also the basis for the clinical effects of chemotherapeutic drugs (Wallace and Starkov, 2000) . Hence, the balance of cell death inhibition and susceptibility within the cancer cell can determine both the transformation process and the therapeutic outcome of cancer treatment. Accordingly, many cellular regulators of apoptosis turned out to be mutated in cancers. Based on these observations, it was speculated that RCCs also contribute to apoptosis induction. A good candidate to make the link between defective RCC function and apoptosis are ROS, as they are often formed when RCCs are partially inhibited. These ROS, which can also be generated in physiological conditions, are (Clementi et al., 1998; Fiorucci et al., 2004) (3) Ceramide synthesis: or depending on cancer type (Ryland et al., 2011) Direct RCC III inhibition and subsequent ROS production (Gudz et al., 1997; Di Paola et al., 2000) Abbreviations: NO, nitric oxide; O 2 , oxygen; RCC, respiratory chain complex; ROS, reactive oxygen species.
Respiratory chain complexes and apoptosis A Lemarie and S Grimm overproduced when the RC is inhibited, as shown for RCC I, II and III (Ott et al., 2007) . The precise molecular processes of how complexes of the RC are inhibited for apoptosis induction are so far only known for complex I and II (see below). In both cases, free electrons are generated from the substrates of the RCC, which are then transferred to molecular oxygen to form ROS. These molecules then act in a pleiotropic way in the cell for apoptosis induction; they crosslink proteins, produce ceramide, oxidize proteins in the mitochondrial permeability transition pore, activate c-Jun N-terminal kinase, oxidize glutathione and damage DNA (Circu and Aw, 2010) .
Complex I in apoptosis
Structure and function of complex I Complex I (NADH dehydrogenase, also called NAD-H:ubiquinone oxidoreductase) is the largest complex of the respiratory chain with 45 separate polypeptides in mammalian cells. Two superstructural 'arms' have been identified: one that anchors the complex in the IMM and is responsible for the translocation of protons, and the other that protrudes into the matrix and constitutes most of the electron transport moiety. The exact mechanism of how complex I couples this electron transport to a vectorial proton translocation remains only incompletely understood. Complex I catalyzes the first reaction in the respiratory chain, the oxidation of NADH to NAD þ , and provides two electrons, which are sequentially transferred from a flavin mononucleotide cofactor to the eight Fe-S clusters in complex I to eventually reduce ubiquinone to ubiquinol (Figure 1 ).
Role of complex I in apoptosis
Complex I was the first complex of the respiratory chain for which a molecular explanation for its role in apoptosis induction was found. Green and colleagues (Ricci et al., 2004) used an ingenious method to detect substrates of caspase-3. They separated proteins by sodium dodecyl sulphate-polyacrylamide gel electrophoresis in one dimension, incubated them with caspase-3 and separated them again by sodium dodecyl sulphatepolyacrylamide gel electrophoresis in the second dimension. Those proteins that were not cleaved ended up on a straight line, whereas those that were cleaved were detected below it. Using this approach they identified NADH dehydrogenase (ubiquinone) Fe-S protein 1 (NDUFS1 or p75) of complex I as a substrate for caspase-3. The p75 is-as its name implies-a 75 kDa protein and the largest subunit of complex I. It is localized (Semenza et al., 1996) -Unbalance between sustained glycolysis and inhibited RCC. RCC IV COX activity HIF1a induces miRNA-210 and the subsequent downregulation of COX10 (assembly factor for RCC IV). Glycolysis via TIGAR inhibition: TIGAR inhibits the glycolysis activator fructose 2,6 bisphosphate. (Bensaad et al., 2006) RCC IV SCO2 expression SCO2 is necessary for the correct assembly and activity of complex IV (Matoba et al., 2006) Abbreviations: COX, cytochrome c oxidase; HIF1a, hypoxia-inducible factor-1a; LDH, lactate dehydrogenase; NADH, nicotinamide adenine dinucleotide; OxPhos, oxidative phosphorylation; PDH, pyruvate dehydrogenase; RCC, respiratory chain complex; SCO2, synthesis of cytochrome c oxidase 2; TCA, tricarboxylic acid; TIGAR, TP53-induced glycolysis and apoptosis regulator.
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A Lemarie and S Grimm in the IMM, but the loop that is cleaved by caspase-3 seems to be accessible from the intermembrane space of mitochondria. The cleavage of p75 leads to an inhibition of complex I, mitochondrial transmembrane potential (DC M ) collapse and ROS production. A dominantnegative p75 mutant (p75D255A), which cannot be cleaved any more, sustained DC M when introduced into cells and led to a delay in the loss of plasma membrane integrity. Importantly, this mutant also diminished the formation of ROS. Although the most obvious interpretation of these results is that the cleavage of p75 inactivates it and this is underlying the effects on apoptosis, it cannot be excluded that the p75 protein fragments have an additional effect such as acting as a dominant-negative variant. In any case, it can be concluded that p75 is a major substrate for caspase-3 and crucial for the execution of apoptosis. Interestingly, this process appears to affect immunological tolerance. Tolerance can be induced by the injection into mice of dendritic cells that had engulfed apoptotic cells expressing wild-type p75, whereas this was not the case for the noncleavable p75D255A mutant (Kazama et al., 2008) . Hence, the cleavage of p75 by caspases seems to be important for the induction of immune tolerance by apoptotic cells, possibly because it leads to inactivation of an immunostimulatory activity in the dying cells and results in tolerance induction. Killer lymphocytes release granzymes and serine proteases in order to destroy their target cells (Cullen and Martin, 2008) . Cell death by granzyme A (GzmA) is morphologically apoptotic but caspase inhibition does not prevent this process, nor does the activation of antiapoptotic Bcl-2 (B-cell lymphoma 2) family members. Interestingly, GzmA fails to disrupt the mitochondrial outer membrane (MOM), an event that is otherwise causing apoptosis induction, as apoptogenic factors from the intermembrane space are thought to be required for apoptosis induction (Martinvalet et al., 2005) . ROS have been shown to underlie cell death effect by GzmA as superoxide scavengers block cell death (Martinvalet et al., 2005) . Martinvalet et al. (2008) showed that, despite lacking a mitochondrial targeting sequence, GzmA makes its way into the mitochondrial matrix through the Tim/Tom twin translocases and cleaves NADH dehydrogenase (ubiquinone) Fe-S protein 3 (NDUFS3), another subunit of RCC I, after lysine 56 (Martinvalet et al., 2008) . NDUFS3 is an Fe-S protein but does not contain a transmembrane domain and therefore seems to be localized to the matrix part of the complex. Although the exact molecular understanding is still lacking, it has been demonstrated that the cleavage of NDUFS3 leads to the formation of ROS and to cell death. When the researchers introduced a proteaseresistant mutant of NDUFS3, they observed a reduction of GzmA-and not GzmB-induced cell death. It will be interesting to see if the NDUFS3 fragment generated by GzmA causes ROS formation and apoptosis when expressed into cells. On the other hand, if it is the inhibition of NDUFS3 that is responsible for the effects, a knockdown of this protein should exert the same effect on apoptosis. Alternatively, a reduction of the protein could also cause a disturbance of complex I assembly similar to what was observed with complex II (see below).
An unexpected role of calpain 10 in connection with complex I inhibition was recently uncovered (Arrington et al., 2006) . Calpains are proteolytic enzymes known to respond to calcium increase and thereby get activated. Calpain 10 was found in association with mitochondrial membranes in the intermembrane space and the matrix of this organelle. With NADH dehydrogenase (ubiquinone) flavoprotein 2 (NDUFV2) and ND6, two subunits of complex I were identified as substrates for calpain 10. In line with this, calcium increase inhibited complex I, and when a calpain inhibitor was applied, this effect was mitigated. Hence, it is plausible, although not yet experimentally documented, that upon apoptosis induction, the increase in mitochondrial Ca 2 þ causes the activation of calpain 10 and the subsequent cleavage of NDUFV2, and ND6 leads to the inactivation of complex I similar to the effects seen with caspase-3 or GzmA.
Complex I is known to generate ROS in two ways as observed in isolated mitochondria from various tissues: one is influenced by the NADH/NAD ratio in the cells that, when increased and the RC is inhibited at the same time, allows the flavin mononucleotide molecule within complex I to transfer electrons to molecular oxygen (Kudin et al., 2004; Kussmaul and Hirst, 2006) . The other scenario is called reverse electron transport when the ubiquinol pool increases under high Dp by, for example, respiration on succinate. Electrons are then transferred from QH2 through complex I (Cino and Del Maestro, 1989) . It is suggestive to assume that the reduced flavin mononucleotide is then also the site of electron transfer to O 2 but this has not yet been unequivocally proven (Murphy, 2009) . It is unknown whether complex I is using the same processes to generate ROS during apoptosis when either NDUFS1 or NDUFS3 is cleaved.
An alternative or additional explanation for the effects of complex I on cell death could be the reduction of the ATP level, which then can contribute to apoptosis. In this regard, it is interesting to note that when the mitochondrial outer membrane is permeabilized under caspase-inhibition conditions, it seems to be the reduction of the ATP level through the inhibition mainly of complex I that is then responsible for cell death (Lartigue et al., 2009) .
Hence, complex I is a sensor for caspase-3/GzmA activation (Ricci et al., 2004; Martinvalet et al., 2008) and calcium increase via calpain 10 activation (Arrington et al., 2006) as common features of apoptotic cells (summarized in Figure 3 ) and its inactivation is necessary for at least some features of apoptosis.
Complex II in apoptosis
Structure and function of complex II RCC II is, besides RCC I, the second entry point of reducing equivalents into the RC via FADH 2 generated Respiratory chain complexes and apoptosis A Lemarie and S Grimm by the oxidation of succinate to fumarate in the tricarboxylic acid (TCA) cycle. The complex II heteroligomer provides electrons to reduce CoQ to QH2 (Lenaz and Genova, 2010) (Figure 1 ). RCC II consists of only four subunits, all of which are encoded by nuclear DNA and as such is the smallest RCC. Another particularity is that this complex is the only one in the RC not to pump protons across the IMM (Rutter et al., 2010) . In eukaryotic cells, two components, SDHA and SDHB, constitute the hydrophobic head that protrudes into the matrix. They form the catalytic core that is able to oxidize succinate (which binds to SDHA) and carries electrons from this TCA cycle substrate to the FAD cofactor in SDHA and finally to the 3 [Fe-S] clusters in SDHB Rutter et al., 2010) . At this stage, electrons can be captured in vitro by artificial electron acceptors and the corresponding enzymatic activity is called SDH activity (Lemarie et al., 2011) . This catalytic core is associated with a hydrophobic tail formed by two transmembrane proteins, SDHC and SDHD, both of which also project a short segment of amino acids into the intermembrane space (Yankovskaya et al., 2003; Sun et al., 2005) . Of note, their membrane domains contain as an additional redox group a heme b bound at the interface between SDHC and SDHD whose role in complex II function is unknown at the moment in mammals (Lemarie and Grimm, 2009) and not yet fully defined in yeast (Oyedotun et al., 2007) and Escherichia coli (Tran et al., 2007) . Two CoQ-binding sites appear to reside at the SDHC/SDHD level: Q P (proximal) and Q D (distal) Rutter et al., 2010) . CoQ reduction at the Q P site, which has a high affinity for CoQ (Maklashina and Cecchini, 2010) , is a two-step process with the formation of a partially reduced semiquinone with the first electron transmitted. Only the second electron then fully reduces semiquinone leading to QH2 (Guo and Lemire, 2003; Rutter et al., 2010) . The semiquinone radical, contrary to what happens at RCC I and III (Lenaz and Genova, 2010) , appears to be stabilized at the Q P site for complete reduction, avoiding excessive electron leakage under normal physiological conditions (Guo and Lemire, 2003; Rutter et al., 2010) . The entire electron transfer from succinate at the catalytic site of Figure 3 Complex I in apoptosis induction: schematic diagram of the inhibition of complex I for apoptosis induction. The protein subunits that are cleaved by active caspase-3, granzyme A or putatively by calpain 10 are highlighted along with the disrupted electron flux between the flavin mononucleotide (FMN) group and the different iron-sulphur (Fe-S) clusters (N1a to N6b). As a result, the cellular ATP level drops, the mitochondrial transmembrane potential (DC M ) collapses and the electron leakage at complex I is used to generate ROS for apoptosis induction. Each protease pathway is summarized on the diagram and detailed in the text. Tom/Tim: twin translocases present in the mitochondrial outer membrane (MOM)/IMM; MOMP: MOM permeabilization.
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SDHA to CoQ at the Q P site constitutes the SQR activity of RCC II, which can, just as the SDH activity, be measured in vitro with the appropriate enzymatic assay (Lemarie et al., 2011) . The precise molecular mechanisms of ROS production at the complex II level have rarely been explored. Indeed, the ability of complex II to generate ROS was mostly neglected in the 1990s as the common dogma considered RCCs I and III to be the principal sources of mitochondrial ROS (McLennan and Degli Esposti, 2000; Ricci et al., 2003b) , based on studies of chemical inhibition by rotenone and antimycin A, respectively (Lenaz and Genova, 2010) . Nevertheless, different sites for superoxide production have been evoked, for example, at the SDHB/C/D CoQ-binding site (Szeto et al., 2007) possibly through the stabilization of the semiquinone radical (Tran et al., 2006) , at the FAD level in SDHA (Yankovskaya et al., 2003) or between the SDHA-embedded FAD group and a downstream blockade (Guzy et al., 2008; Lemarie et al., 2011) . These mechanisms appear to depend on the respective targets of the chemical inhibitors used or on the specific sequence of the mutations analysed.
Role of complex II in apoptosis
The hypothesis that complex II can contribute to apoptosis developed only relatively recently based on the role of this tetramer in LS, a neurodegenerative disease that is associated with neuronal degeneration and necrosis/apoptosis (Finsterer, 2008) . This was highlighted in the mid-1990s with the discovery of the first SDHA mutation linked to LS (Bourgeron et al., 1995) . This observation was corroborated by various studies showing the proapoptotic effects of specific complex II inhibitors, notably 3-nitropropionate (irreversible inhibitor) and methylmalonate (competitive inhibitor) in neuronal cells (Pang and Geddes, 1997; McLaughlin et al., 1998) . Both reagents target the SDHA succinate-binding site and equally inhibit the SDH and SQR activities (Brusque et al., 2002; Lemarie et al., 2011) . When the tumour-suppressor gene function of complex II subunits was discovered for SDHD, SDHC and SDHB (Baysal et al., 2000; Niemann and Muller, 2000; Astuti et al., 2001) , two mechanisms were evoked to explain the oncogenesis process associated with complex II deficiency: (1) the establishment of a pseudo-hypoxic state leading to HIF1a stabilization in tumours through succinate inhibition of the HIF1a prolyl hydroxylase (PHD), which favours the glycolytic pathway and promotes tumour formation (GimenezRoqueplo et al., 2001; Pollard et al., 2005 Pollard et al., , 2006 Selak et al., 2005; Lehtonen et al., 2007; Cervera et al., 2008) and (2) the long-term generation of sublethal superoxides at the complex II level contributing to either genomic instability and subsequent tumoral development or HIF1a stabilization (Senoo-Matsuda et al., 2001; Ishii et al., 2005; Slane et al., 2006; Guzy et al., 2008) . Various key publications subsequently brought to light the possible role of complex II as a proapoptotic sensor, through the production of deleterious high levels of ROS, which could provide a third explanation as to why complex II subunits are disabled in tumourigenesis. The first study suggesting that complex II is a central mediator during the apoptotic process was performed by Green and colleagues (Ricci et al., 2003a) . They observed that during apoptosis, after mitochondrial outer membrane permeabilization, RCCs I and II are inhibited in a caspase-dependent manner and contribute via ROS production and DC M collapse to apoptotic cell death (Ricci et al., 2003a) . The direct effect of caspase-3 on complex I subunit NDUFS1 was later identified as mentioned above (Ricci et al., 2004) , but the exact, direct or indirect, mechanism by which succinatedependent respiration was altered remained unknown. Schlisio and colleagues demonstrated that neuronal apoptosis induced by NGF withdrawal necessitates a functional complex II, acting as a sensor for apoptosis induction (Lee et al., 2005) . Indeed, nerve growth factor deprivation was shown to activate c-Jun and the downstream proapoptotic pathway mediated by PHD3 (EglN3) to induce apoptosis. Although the c-Junactivated PHD3 is a prolyl hydroxylase involved in HIF1a degradation, the c-Jun-mediated apoptosis appeared to be independent of HIF1a and required the kinesin KIF1Bb. However, complex II inhibition (by either SDHD siRNA or chemical inhibitors) led mainly to succinate accumulation and to the succinate-mediated blockade of PHD3 proapoptotic function. This mechanism was hypothesized to favour tumour progression in surviving neurons (Lee et al., 2005) .
Complex II as a pH sensor for apoptosis. Through a genetic high-throughput screen (Grimm, 2004) , our group isolated various proapoptotic genes, notably SDHC and SDHD (but not SDHA or SDHB). Overexpression of SDHC appeared to inhibit, in a caspaseindependent manner, the SQR activity of complex II without impairing its SDH activity. This generated superoxides at complex II and induced a caspasedependent apoptosis (Albayrak et al., 2003) . Moreover, complex II-deficient hamster CCL16 B9 cells, which appear to not assemble an intact complex II (Lemarie and Grimm, 2009) owing to a SDHC mutation (Oostveen et al., 1995) , were dramatically resistant to numerous structurally diverse anticancer drugs and cytokines, reagents that were shown to specifically reduce complex II activity before overt apoptotic cell death (Albayrak et al., 2003) . Subsequent studies were then dedicated to understand the precise mechanisms by which the anticancer compounds and cytokines inhibit complex II during the early stages of apoptosis. We found that all the reagents reduce complex II specifically at the SQR level without impairing the upstream SDH activity (Lemarie et al., 2011) . Of note, the complex II-specific inhibitor thenoyltrifluoroacetate, which targets the Q P -binding site , recapitulated these effects (Krahenbuhl et al., 1991; Lemarie et al., 2011) , suggesting that this downstream block of complex II favours disruption of the electron transfer and leakage to molecular oxygen between the Respiratory chain complexes and apoptosis A Lemarie and S Grimm still active succinate-binding site of SDHA and the inaccessible Q P site to generate superoxides (Lemarie et al., 2011) . Furthermore, we provided evidence that this specific uncoupling was accomplished through intracellular acidification, which includes a mitochondrial pH decrease. Early during the apoptotic process the cellular pH drops (Lagadic-Gossmann et al., 2004) . This seems to impact the interactions within complex II and leads to the release of the catalytic SDHA/SDHB subunits from the membrane-anchoring subunits of complex II into the matrix, creating an uncoupling between the still functioning SDHA/SDHB subcomplex and the SDHC/SDHD anchor (Lemarie et al., 2011) . Interestingly, two other cases of complex II dissociation into subcomplexes were reported: the first in a patient presenting a SDHA mutation and suffering from LS (Pagnamenta et al., 2006) , and the second in cells responding to ionizing irradiation, which induces ROS in a complex II-dependent manner (Dayal et al., 2009) . In summary, our results led us to propose the model depicted in Figure 4 in which apoptosis is initiated by an early cellular pH change that causes the specific disintegration of complex II by the release of the subcomplex SDHA/SDHB from the membrane-anchoring Figure 4 Complex II in apoptosis induction: schematic presentation of the transition from a functional complex II (a) to the specific release of the SDHA/SDHB subcomplex into the matrix in response to the intracellular and mitochondrial pH (pH i , pH M ) acidification (b). This complex II dissociation uncouples its two enzymatic activities (SDH and SQR activities) for superoxide (O 2 .À ) production and apoptosis (c). For more detailed information, see text.
Respiratory chain complexes and apoptosis
A Lemarie and S Grimm subunits. As this subcomplex is still enzymatically active (Nakamura et al., 1996; Cecchini, 2003) , it can remove electrons from its substrate succinate and transfer them to molecular oxygen. This uncontrolled enzymatic activity thereby generates excessive ROS for apoptosis induction (Albayrak et al., 2003; Lemarie et al., 2011) . Hence, we concluded that complex II is a mitochondrial sensor for pH change as a widespread initiating event in apoptotic cells (Lagadic-Gossmann et al., 2004) and that its specific inhibition can be sufficient for the induction of apoptosis through mitochondrial ROS production. The precise executioners of the apoptotic cascade mediated by RCC II-induced ROS in response to anticancer drugs still have to be determined, but caspases seemed to form the apex of this apoptotic cascade (Lemarie et al., 2011) . As this process is expected to be curtailed in tumours with metabolically downregulated respiration and in cancer cells with mutations in SDH subunits, the disruption of this essential pH sensor for apoptosis induction can explain why these cells can survive adverse growth conditions and form tumours. Concerning apoptotic pathways mediated by early acidification, it is fair to state that the RCC II sensor function is certainly not the only mediator of apoptosis induction, as caspases, endonucleases and Bcl-2 family members have also been shown to be directly activated by pH acidification (LagadicGossmann et al., 2004) . However, the complex II pH sensor can be sufficient for apoptosis induction and the deletion of such a proapoptotic sensor leads to apoptosis resistance. Of note, it would be interesting to extend our observations to scenarios of physiopathological acidosis, for example, metabolic acidosis or lactic acidosis associated with hypoxic conditions, and determine whether this likewise induces a complex II-dependent apoptotic cell death. Although a direct comparison of complex I-and complex II-dependent mechanisms for apoptosis induction has not yet been performed, the effects on complex II could take place earlier during apoptosis as pH change occurs before caspase activation in most apoptosis models. Moreover, the subcomplex SDHA/ SDHB remains functional for ROS generation in the matrix after the dissociation, in contrast to the fast and almost complete disruption of complex I activity by caspases (Ricci et al., 2004) . Therefore, the production of superoxides by complex II could exceed other cellular changes during cell death and produce a particular strong apoptotic signal. Two assembly factors for complex II were discovered lately, one acting on SDHA flavination (SDHAF2; Hao et al., 2009 ) and the other putatively on SDHB (SDHAF1; Ghezzi et al., 2009) . It can be hypothesized that these proteins render complex II dissociation reversible and reassemble the subcomplexes, in contrast to the irreversible NDUFS1 cleavage observed in complex I inhibition (Ricci et al., 2004) . In line with this, Tcm62, another complex II assembly factor discovered in yeast (Dibrov et al., 1998) , and prohibitin (PHB), its putative mammalian homologue, have been implicated in cell death inhibition following growth factor withdrawal (Vander Heiden et al., 2002) . Interestingly, both Tcm62 and PHB were shown to act as mitochondrial chaperones and to be required for mitochondrial respiratory function (Dibrov et al., 1998; Klanner et al., 2000; Nijtmans et al., 2000 Nijtmans et al., , 2002 . This could indicate that members of this chaperone family can re-assemble complex II during apoptosis and thereby decrease ROS formation and cell death, making this process subject to additional levels of regulations.
Consequences of complex II-generated ROS for apoptosis and tumourigenesis. Our model depicts complex II as being directly targeted by pH acidification. However, it is also possible that other kinds of signals can produce the same inhibitory effect, that is, a specific inhibition of the SQR activity with minimal impairment of the SDH activity leading to ROS generation and to apoptosis. Various studies demonstrated that particular complex II subunit mutations or their downregulation also induce apoptosis through ROS production. Pioneer work conducted by Ishii et al. (1998) has shown that a SDHC mutant at the CoQ-binding site (mev-1 mutant) induced mitochondrial superoxide production and apoptosis in various models (detailed in Table 3 ) through the specific inhibition of the SQR activity without SDH function impairment. Other SDHB/C/D mutations at the CoQbinding site have been shown to reproduce the effects and are described in Table 3 . Similar observations were made with different complex II inhibitors targeting succinate or CoQ-binding sites of SDHA or SDHB/ C/D, respectively (Table 3) . Indeed, the same concentration of thenoyltrifluoroacetate, a-tocopheryl succinate and aptenins, which all target the CoQ-binding site, can induce a potent inhibition of the SQR activity with no or weak SDH alteration and lead to significant ROS generation and apoptotic or autophagic cell death (Table 3) . On the other hand, succinate competitors (malonate derivatives) or a chemical inhibitor (3-nitropropionate) curtailed both SQR and SDH activities and failed to induce similar ROS production and/or apoptosis in the same cell lines (Table 3) . Altogether, these results illustrate that specific inhibitors and mutations of complex II subunits can reproduce the uncoupling effect between SQR and SDH activities seen in the pH-sensor model and generate ROS for apoptosis induction.
Other mutations of complex II subunits induce a decrease of the expression of their mRNA or their protein and lead to the depletion of the assembled complex II as revealed for a SDHB mutant in Drosophila (Walker et al., 2006) and for a SDHC mutant in hamster CCL16 B9 cells (Lemarie and Grimm, 2009 ). Both of these SDHB and SDHC mutants were associated with mild ROS production and with death or tumourigenesis, respectively (Slane et al., 2006; Walker et al., 2006) . This downregulation appears to be very similar to complex II mutations in PGL/PH as a large majority of these tumours do not express a correctly assembled complex II (van Nederveen et al., 2009) . Whether or not these particular mutations leading to impairment of complex II assembly, like the mutations in the coding sequence for its subunits, are associated with ROS production is a critical question, but the detection of ROS and notably of superoxides depends on the sensitivity of the method used, the cell specifics, the culture conditions, the different kinetics and the level of ROS production, as well as the mechanisms of their generation. In order to assess whether the reduction of complex II assembly through subunit downregulation can lead to ROS formation and finally to apoptosis or tumourigenesis, the data obtained by RNA interference (RNAi) could be instructive (summarized in Table 4 ). We and others have shown that depletion of SDHA, SDHB, SDHC or SDHD by RNAi failed to induce significant apoptosis. This is in accordance with our model showing that deletion of this apoptosis sensor renders cells resistant to cell death. In addition, a majority of studies using RNAi against SDHA/B/C/D failed to detect significant ROS production, except one study showing a moderate mitochondrial superoxide production with SDHB shRNA (Guzy et al., 2008) (Table 4) . It is conceivable that in those experiments, which did not show oxidative stress, the techniques used for ROS detection were not sensitive enough or that the kinetics of ROS production did not correspond to the time points of measurement, notably for transient RNAi experiments. However, it is also possible that there is intervariability between the cellular systems used or in the cellular equipment of antioxidants (such as superoxide dismutase, catalase or glutathione) leading to the suppression of ROS. Concerning those SDHA RNAi experiments that did not detect ROS overproduction even with the sensitive mitochondriatargeted probe mitoSOX (Table 4) , based on our observation that an equal inhibition of both SQR and SDH activities did not induce superoxide production, it was expected that the suppression of SDHA by RNAi, 
Respiratory chain complexes and apoptosis A Lemarie and S Grimm which inhibits both activities, failed to induce ROS overproduction. For the downregulation of SDHB, SDHC or SDHD, it was shown by our group and others that the resulting disassembly of complex II did not impair the mitochondrial localization of SDHA (Smith et al., 2007; Favier et al., 2009; Lemarie and Grimm, 2009) , whereas all the other subunits were absent (Lemarie and Grimm, 2009; van Nederveen et al., 2009) . This soluble matrix SDHA, even at low quantities , could suffice to catalyse a residual SDH activity through succinate oxidation and then generate an electron leakage to molecular oxygen because of the absence of downstream electron acceptors. This phenomenon could explain the ROS production observed in two studies during SDHB downregulation (Smith et al., 2007; Guzy et al., 2008) . To conclude, mutations in complex II subunits found in cancer and associated with complex disassembly could drive the cell fate towards tumourigenesis by the confluence of several effects as detailed in Table 5 . Tumourigenesis (Selak et al., 2005) (3) Subtle and chronic ROS production (optional). (Smith et al., 2007) Hypothesis: generation through the remaining matrix SDHA. (Slane et al., 2006 ) Consequences: cellular damages and/or HIF1a stabilization. (Guzy et al., 2008) SDHA (rare) (1) Disruption of complex II function as a sensor for apoptosis. SDHAF2 (rare) Consequence: cell death resistance.
(2) Succinate accumulation. (Hao et al., 2009 ) Consequence: activation of the HIF1a survival pathway.
Tumourigenesis (Burnichon et al., 2010) (3) Probably no ROS production. (Lemarie et al., 2011) Hypothesis: the complete disruption of a functional SDHA and of the associated SDH activity does not allow any ROS generation.
Abbreviations: HIF1a, hypoxia-inducible factor-1a; ROS, reactive oxygen species; SDH, succinate dehydrogenase.
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Interestingly, it appears that, contrary to the SDHA/ SDHB/SDHC/SDHD and SDHAF2 mutants found in tumours, the SDHA and SDHAF1 mutants identified in LS and leukoencephalopathy, respectively, retain a significant complex II activity (20-60% according to the studies; Bourgeron et al., 1995; Parfait et al., 2000; Horvath et al., 2006; Levitas et al., 2010) and also show a decreased but still productively assembled complex II in mitochondria (Van Coster et al., 2003; Pagnamenta et al., 2006; Ghezzi et al., 2009) . A SDHA mutant identified in a LS patient is associated with succinate accumulation, HIF1a stabilization and superoxide production , as described for the SDHB/C/D mutations in PGL/PH. Succinate accumulation was also observed in a carrier of a SDHAF1 mutation (Brockmann et al., 2002; Ghezzi et al., 2009) . As necrosis or/and apoptosis are characteristics of LS (Finsterer, 2008) and as ROS-mediated cell death was reported to occur in LS models linked to SDHA mutations (Mast et al., 2008; Mbaya et al., 2010) , it could be hypothesized that such SDHA/SDHAF1 mutants lead to neurodegeneration and not to tumourigenesis owing to the maintenance of the apoptosis sensor function of complex II via the remaining assembled complex II and not owing to the HIF1a signalling pathway. Of note, SDHAF1 mutations, thought to impair the assembly of the Fe-S cluster in SDHB, lead to a stronger decrease of SQR than SDH activity (Ghezzi et al., 2009) . It is thus conceivable that the uncoupling generated at the SDHB level may be the origin of an electron leakage associated with ROS generation and neuronal cell death. SDHA mutants appear to induce an equal SDH and SQR activity inhibition (Bourgeron et al., 1995; Parfait et al., 2000; Levitas et al., 2010) and it could be hypothesized that such SDHA mutations generate the observed superoxide production directly at the SDHA level and not between the succinate catalytic site and the CoQ-binding site.
Complex II and cell death in neurons: cell-specific apoptotic mechanisms. In relation to the complex II mutations found in neurodegenerative diseases like LS, it appears that neurons are very sensitive to complex II-mediated apoptosis. Different studies demonstrated that inhibition of complex II governs a direct apoptotic process in neurons through cell-specific pathways. It was recently shown that neurons, which require high levels of energy, are sensitive to complex II-induced OxPhos impairment and this results in a rapid ATP decrease (Mandavilli et al., 2005; Liot et al., 2009; Mbaya et al., 2010) , contrary to other cell types, which did not show such a rapid ATP drop in response to complex II inhibition by a SDHC mutant or by the inhibitor thenoyltrifluoroacetate (Senoo-Matsuda et al., 2001; Ishii et al., 2007; Soller et al., 2007; Byun et al., 2008) . In neurons, this ATP decrease induced by either 3-nitropropionate, aptenin or a SDHA mutant causes a profound alteration of the intracellular and mitochondrial calcium homeostasis, which then leads to an amplification of mitochondrial ROS formation by complex II and probably by other sources, DC M loss and finally neuronal apoptotic cell death (Liot et al., 2009; Mbaya et al., 2010) .
RC-based strategies in cancer therapy?
To conclude, the inhibition of the RC is widespread in cancer and intimately connected to apoptosis resistance. Seemingly contradictory, the inhibition of RCC also leads to ROS formation and apoptosis induction. This is achieved by the specific way of how the RCCs are inhibited for cell death. A case in point is that the downregulation of complex II subunits does not lead to apoptosis (Lemarie and Grimm, 2009) , whereas its specific inhibition by dissociation does (Lemarie et al., 2011) . How then can cancer researchers exploit the defects of the respiratory chain for therapeutic gain? Can we reactivate the RC in cells affected by the Warburg effect and thereby reactivate the apoptosis sensors of the RCC? Dichloroacetic acid is a compound that inhibits the enzyme pyruvate dehydrogenase kinase, thus shifting the metabolism of cancer cells from glycolysis back to OxPhos. This has been shown to sensitize malignant cells to apoptosis and consequently dichloroacetic acid has been proposed as a therapeutic compound (Bonnet et al., 2007; Michelakis et al., 2008 Michelakis et al., , 2010 . Other reagents with similar effects have also been used, for example, the glycolysis inhibitors 3-bromopyruvate and 2-deoxyglucose (Halicka et al., 1995; Xu et al., 2005) , but they all must be carefully assessed for toxic side effects as they target a quantitative rather than a qualitative difference in the glycolysis rate between cancer and normal cells.
Another class of mitochondrially targeted anticancer agents, the so-called mitocans (reviewed in Gogvadze et al., 2009; Ralph and Neuzil, 2009; Ralph et al., 2010) , have been designed to specifically use the apoptosis sensor function of the RCCs to induce cell death in cancer cells. Different inhibitors of complex I (for example, tamoxifen; Moreira et al., 2006) , complex II (for example, fenretinide; Cuperus et al., 2010) or complex III (for example, adaphostin; Le et al., 2007) markedly induce ROS and apoptosis in tumour cells. One of the most promising drugs in this field is the vitamin E derivative a-tocopheryl succinate (Dong et al., 2007 (Dong et al., , 2008 (Dong et al., , 2009 ) and its mitochondrial targeted analogue mitoVES (Dong et al., 2011a, b) developed by the Neuzil group. These compounds were shown to specifically target the Q P site of complex II for ROS generation by enzymatic uncoupling (see above) and elicit apoptosis induction in tumours in vitro and in vivo. The apoptotic cascade initiated by these mitochondrial ROS was demonstrated to involve specific Bcl-2 family members identified as the Noxa-Bak axis and the subsequent mitochondrial outer membrane permeabilization and effector caspase activation (Prochazka et al., 2010; Dong et al., 2011b) . Of note, as for the reagents that target glycolysis, a crucial aspect is the specificity of these drugs, and further studies are aimed at increasing their efficiency and decreasing potential side effects.
Consequently, based on these exciting new findings and the recent discoveries in this field that we have covered here, it emerges that the precise understanding of how the RC contributes to apoptosis induction could in the future lead to a more informed and targeted anticancer treatment.
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